Clinical Trials Browser

Phase 2 × Lymphoma × atezolizumab × Clear all

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03465891 2021-01-12

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Phase 2 Terminated

2 enrolled 6 charts

Lymphoid

Lymphoma, Recurrence

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.